Hepatitis C treatment: latest news

Hepatitis C treatment resources

  • Hepatitis C

    Hepatitis C virus (HCV) is chiefly transmitted by blood-to-blood contact. When the blood of a person with hepatitis C enters the bloodstream of another person,...

    From: Factsheets

    Information level Level 2
  • Hepatitis C

    Hepatitis C is a serious infection caused by a virus.It damages the liver, which performs essential functions in the body.Some people have hepatitis C for...

    From: The basics

    Information level Level 1
  • Hepatitis C treatment

    Deciding on the best time to take treatment for hepatitis C is not straightforward.It’s important to get support and advice to help you with this...

    From: The basics

    Information level Level 1
  • Hepatitis C virus treatment

    The current preferred treatment regimen for HCV infection is a combination of peginterferon alfa (given by injection) plus ribavirin (given orally). Interferons are human proteins that...

    From: HIV treatments directory

    Information level Level 4
  • Treatment for hepatitis C

    Treatments are available for hepatitis C and aim to cure the condition. People with HIV who are newly diagnosed with hepatitis C should consider the pros and...

    From: Booklets

    Information level Level 2

Hepatitis C treatment features

Hepatitis C treatment in your own words

Hepatitis C treatment news from aidsmap

More news

Hepatitis C treatment news selected from other sources

  • Hepatitis C patients stage sit-in to demand access to new treatment

    Protest at Madrid hospital aims to shame the government into releasing more funds.

    19 hours ago | El Pais
  • US FDA approves AbbVie hepatitis C drug, costs $83319 for 12 weeks

    U.S. health regulators on Friday approved AbbVie's all-oral treatment for hepatitis C, and the company said the drug would cost $83,319 for a typical 12-week plan, a bit below its huge selling competitor Sovaldi from Gilead Sciences.

    20 hours ago | Reuters
  • Cigna's Demonstration of “Real World” Effectiveness for Hepatitis C New Drug

    Cigna is monitoring the health outcomes of customers with hepatitis C who have undergone treatment using a prescription combination with the drug Sovaldi. Cigna found that 91.1% of customers achieved a sustained virologic response (SVR). Customers who have an SVR when tested 12 weeks after the completion of treatment are considered cured.

    17 December 2014 | Insurance News Net
  • Class Action Lawsuit Challenges Exorbitant Pricing of Gilead’s Hepatitis-C Drug Sovaldi

    Gilead has been selling a twelve week regimen of Sovaldi in the United States for approximately $84,000, or $1,000 per pill. This is significantly more than the original price projection for Sovaldi, and in sharp contrast to the prices at which the drug is being made available in other countries. Gilead recently announced its intention to make Sovaldi available in 91 developing countries at deeply discounted prices, and the drug is reportedly available in Egypt for 99% below the U.S. price. This obvious pricing paradox is under investigation by the Senate Finance Committee, which has questioned if the market for Sovaldi “is working efficiently and rationally,” and whether “payors of health care….can carry such a load.”

    12 December 2014 | Chimicles & Tikellis press release
  • Philadelphia Agency Sues Gilead Over Price Of Hepatitis Drug

    Philadelphia's transit agency has sued Gilead Sciences Inc., accusing the company of "price-gouging" on the sale of its $1,000-per-pill hepatitis C drug Sovaldi, the latest salvo in a battle between health-care payers and the pharmaceutical industry.

    11 December 2014 | Nasdaq
  • Will AbbVie's 3-DA regimen prove a compelling competitor to Gilead's Harvoni?

    Later this month, the FDA is expected to approve AbbVie's oral '3-DA' product - comprising Viekirax (ombitasvir/ paritaprevir/ ritonavir) plus Exviera (dasabuvir) - for the treatment of genotype 1 hepatitis C patients. European approval is expected to occur in early 2015 following a positive recommendation from a European Medicines Agency committee last month. Payers in the US are hoping that AbbVie will deliver festive cheer by announcing a notable 'sticker price' discount versus Gilead Sciences' Harvoni brand, which costs $94,500 for a 12-week supply.

    10 December 2014 | Hepatitis C New Drugs
  • FDA declines to approve Bristol-Myers hepatitis drug

    Bristol-Myers said the FDA has asked it for data involving use of daclatasvir with other drugs, and that the company is in discussions with the agency about the scope of the required information.

    27 November 2014 | Reuters
  • Deaths of Japanese patients prompt label change for simeprevir

    The maker of Sovriad (simeprevir) has revised its package insert labeling on the order of Japanese health officials following the deaths of three people who took the hepatitis C drug.

    24 November 2014 | HCP Live
  • Ooh La La: France Negotiates a Steep Discount for Sovaldi From Gilead

    The fixed price reduced the cost by about 27%, and so a 12-week regimen will now be priced at $51,400, instead of $71,100. This makes this the “lowest price in Europe,” according to the Economic Committee for Health Products. There is also stipulation that rebates will be made in the event of “treatment failure,” according to a statement from the agency.

    21 November 2014 | Wall Street Journal
  • NHS asks Nice to delay ground-breaking hepatitis C drug

    Nice is due to finish its final assessment of sofosbuvir in January. It is usual for them to give the NHS three months to find the money or put staff – if needed – in place. NHS England is thought to have asked them to delay this by six months.

    19 November 2014 | Channel 4 News (blog)
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.